These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9822984)

  • 1. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients.
    Balasch J; Fábregues F; Peñarrubia J; Creus M; Vidal R; Casamitjana R; Manau D; Vanrell JA
    J Assist Reprod Genet; 1998 Oct; 15(9):552-9. PubMed ID: 9822984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
    Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
    J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
    Burgués S;
    Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG.
    International Recombinant Human Chorionic Gonadotropin Study Group
    Fertil Steril; 2001 Jun; 75(6):1111-8. PubMed ID: 11384635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between inhibin A and B, estradiol and follicle growth dynamics during ovarian stimulation in normo-ovulatory women.
    Hohmann FP; Laven JS; de Jong FH; Fauser BC
    Eur J Endocrinol; 2005 Mar; 152(3):395-401. PubMed ID: 15757856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens.
    van Santbrink EJ; Fauser BC
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3597-602. PubMed ID: 9360513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial.
    Balen A; Platteau P; Andersen AN; Devroey P; Helmgaard L; Arce JC;
    Hum Reprod; 2007 Jul; 22(7):1816-23. PubMed ID: 17449511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman.
    Hornnes P; Giroud D; Howles C; Loumaye E
    Fertil Steril; 1993 Oct; 60(4):724-6. PubMed ID: 8405534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development.
    Hohmann FP; Laven JS; de Jong FH; Eijkemans MJ; Fauser BC
    Hum Reprod; 2001 May; 16(5):846-54. PubMed ID: 11331627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment.
    Fulghesu AM; Apa R; Belosi C; Ciampelli M; Selvaggi L; Cucinelli F; Caruso A; Mancuso S; Lanzone A
    Horm Res; 2001; 55(5):224-8. PubMed ID: 11740143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
    Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
    Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The step-down principle in gonadotrophin treatment and the role of GnRH analogues.
    Fauser BC; Donderwinkel P; Schoot DC
    Baillieres Clin Obstet Gynaecol; 1993 Jun; 7(2):309-30. PubMed ID: 8358893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.